UK markets close in 5 hours 16 minutes
  • FTSE 100

    6,731.76
    +11.11 (+0.17%)
     
  • FTSE 250

    20,685.75
    +46.41 (+0.22%)
     
  • AIM

    1,175.23
    +0.96 (+0.08%)
     
  • GBP/EUR

    1.1228
    -0.0017 (-0.15%)
     
  • GBP/USD

    1.3624
    +0.0037 (+0.28%)
     
  • BTC-GBP

    27,220.13
    +390.67 (+1.46%)
     
  • CMC Crypto 200

    733.36
    -1.79 (-0.24%)
     
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • DOW

    30,814.26
    -177.24 (-0.57%)
     
  • CRUDE OIL

    52.57
    +0.21 (+0.40%)
     
  • GOLD FUTURES

    1,843.70
    +13.80 (+0.75%)
     
  • NIKKEI 225

    28,633.46
    +391.25 (+1.39%)
     
  • HANG SENG

    29,642.28
    +779.51 (+2.70%)
     
  • DAX

    13,868.04
    +19.69 (+0.14%)
     
  • CAC 40

    5,612.60
    -4.67 (-0.08%)
     

Publication of Supplementary Prospectus

Acacia Pharma Group plc
·4-min read

Publication of Supplementary Prospectus

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

Cambridge, UK and Indianapolis, US – 16 December 2020: Acacia Pharma Group plc (“Acacia Pharma” or the "Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that, further to the announcement on 15 December 2020 regarding the amendment of its Investment Agreement with Cosmo Pharmaceuticals (the "Amendment Agreement"), a Supplementary Prospectus in relation to the issue of further shares to Cosmo Pharmaceuticals under the Amendment Agreement, which was approved by the FCA, has been published on the Company’s website: https://acaciapharma.com/uploads/default/news/Acacia_Pharma_Group_plc_Prospectus_December_2020.pdf

It is anticipated that admission of the 2,099,958 New Ordinary Shares to trading on the regulated market of Euronext Brussels will occur on 18 December 2020, and a further announcement will be made once admission has become effective.

The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following issue of the New Ordinary Shares, the Company's total issued share capital will comprise of 89,597,951 ordinary shares with one voting right per share. The Company does not hold any ordinary shares in treasury. Therefore the total number of voting rights in the Company will be 89,597,951.

###

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com

International Media
Mark Swallow, Frazer Hall, David Dible
Citigate Dewe Rogerson
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com

US Investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com

Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

www.acaciapharma.com

Forward looking statements

This announcement includes forward-looking statements, which are based on current expectations and projections about future events. These statements may include, without limitation, any statements preceded by, followed by or including words such as "believe", "expect", "intend", "may", "plan", "will", "should", "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements may and often do differ materially from actual results. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and investments, including, among other things, the development of its business, trends in its operating industry, and future capital expenditures and acquisitions. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's business, results of operations, financial position, prospects, growth or strategies and the industry in which it operates. Save as required by law or applicable regulation, the Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise. Forward-looking statements speak only as of the date they are made.